How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Direct-To-Consumer (DTC) Genetic Testing Market
- By Test Type: Ancestry Testing, Health Risk Assessment, Carrier Screening, Pharmacogenomics, Wellness and Lifestyle
- By Sample Type: Saliva, Buccal Swab, Blood, Hair Follicle
- By End User: Individual Consumers, Healthcare Professionals, Researchers
- By Distribution Channel: Online Direct Sales, Pharmacies, Retail Stores
- By Price Range: Low-Cost Basic Tests, Mid-Range Comprehensive Panels, Premium Customized Testing
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Ancestry Testing leads By Test Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.175 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.183 →
Full report · locked preview
Everything inside the Direct-To-Consumer (DTC) Genetic Testing Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →AncestryDNA (Ancestry.com)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →23andMe Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →MyHeritage Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Invitae Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Living DNA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →FamilyTreeDNA (Gene by Gene
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Ltd.)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Nebula Genomics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Helix OpCo Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Vitagene
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Orig3n Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →CircleDNA (Prenetics)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →TellmeGen
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →DNAfit (Prenetics)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Gene by Gene Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Veritas Genetics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Ancestry Testing55.3
- Health Risk Assessment14.8
- Carrier Screening6.5
- Pharmacogenomics13.6
- Wellness and Lifestyle9.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- AncestryDNA (Ancestry.com)11.5
- 23andMe Inc.19.4
- MyHeritage Ltd.12.9
- Invitae Corporation8.9
- Living DNA10.3
- FamilyTreeDNA (Gene by Gene8.9
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.0
- Europe23.8
- Asia Pacific20.1
- Latin America13.3
- Middle East and Africa10.9
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| AncestryDNA (Ancestry.com) | 77 | 73 | 90 | 85 | 82 | 76 | 81 |
| 23andMe Inc. | 90 | 89 | 87 | 77 | 87 | 75 | 84 |
| MyHeritage Ltd. | 69 | 86 | 81 | 70 | 78 | 87 | 79 |
| Invitae Corporation | 78 | 67 | 82 | 76 | 64 | 80 | 75 |
| Living DNA | 68 | 66 | 62 | 75 | 69 | 62 | 67 |
| FamilyTreeDNA (Gene by Gene | 67 | 56 | 59 | 46 | 66 | 61 | 59 |
| Ltd.) | 58 | 54 | 59 | 61 | 60 | 41 | 56 |
| Nebula Genomics | 47 | 36 | 54 | 52 | 52 | 39 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- AncestryDNA (Ancestry.com)
- 23andMe Inc.
- MyHeritage Ltd.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| AncestryDNA (Ancestry.com) | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| 23andMe Inc. | ✓ | ✓ | ◐ | ◐ | ◐ | ✓ |
| MyHeritage Ltd. | ◐ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Invitae Corporation | ✓ | ◐ | ✓ | ◐ | ◐ | ✓ |
| Living DNA | ◐ | − | ◐ | ◐ | − | ◐ |
| FamilyTreeDNA (Gene by Gene | ✓ | ◐ | ◐ | − | ✓ | − |
| Ltd.) | ◐ | − | − | − | ◐ | − |
| Nebula Genomics | − | − | ◐ | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Challenger2
Strong scale, closing on the leaders.
Contender1
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Test Type in North America, then scale across Direct-To-Consumer (DTC) Genetic Testing Market — a $475M beachhead inside a $7.79B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Ancestry Testing
Best fit — highest urgency & budget in Test Type.
Health Risk Assessment
Strong fit — clear ROI and a fast path to value.
Carrier Screening
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Test Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Sample Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Test Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Direct-To-Consumer (DTC) Genetic Testing Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Direct-To-Consumer (DTC) Genetic Testing Market is a high-growth opportunity — $1.14B by 2033, compounding at 11.4%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.4% CAGR
Demand compounds through 2033, outpacing GDP across Test Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Test Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Sample Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Direct-To-Consumer (DTC) Genetic Testing Market — a $2.32B market by 2033. Plan: grow share from 9.3% to 18.1%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.3% | 18.1% | Ahead |
| Revenue | $230M | $420M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 35.2% | 38.9% | At risk |
| Customer retention | 85.6% | 96.9% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Test Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Sample Type capability
A defensible second engine — invest in Sample Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Test Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Sample Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $51M capacity & capability investment
- Greenlight bolt-on M&A in Sample Type
- Authorise North America expansion plan
- Fund R&D program for Test Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentOn track
Sales deck · value proposition
Win the Direct-To-Consumer (DTC) Genetic Testing Market conversation — a $1.28B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Test Type
Goal Grow share in Test Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Direct-To-Consumer (DTC) Genetic Testing Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Direct-To-Consumer (DTC) Genetic Testing Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Direct to Consumer (DTC) DNA Test Kits Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportDirect-to-consumer DNA Testing Market
Market size, share, segmentation and regional forecast.
$636M market · 2025 base year
View reportOndansetron Hydrochloride Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportBuckminsterfullerene Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportAntimicrobial Silicone Masterbatch Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportNettle Root Extract Market
Market size, share, segmentation and regional forecast.
$990M market · 2025 base year
View reportSialic Acid Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportDirect Ray Disinfection Robot Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportNephrostomy Catheters Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportDirect Primary Care Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportSleeve Rubber Stopper Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportL-Arginine HCL Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy